ReviewInternational journal of molecular sciences2018
Clinical and Molecular Aspects of Vitiligo Treatments.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04320160 (Structural Evaluation of Human Melanocytes After the Use of Autologous Platelet-rich Plasma), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Structural Evaluation of Human Melanocytes After the Use of Autologous Platelet-rich Plasma (PRP) Versus Fractional Carbon Dioxide Laser (Fr:CO2 Laser) in Treatment of Vitiligo: (A Histological, Immunohistochemical and Molecular Study )
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Efficacy of Janus kinase inhibitor combined with phototherapy in non-segmental vitiligo: systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis.Lasers in medical science · 2021Pooled it
- JAK Inhibitors for the Treatment of Vitiligo: Current Evidence and Emerging Therapeutic Potential.Drugs · 2025Review
- The immunological pathogenesis of vitiligo and the potential role of mesenchymal stromal/stem cells in its treatment.Journal of translational medicine · 2025Review
- Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location.Dermatology and therapy · 2024Article
- The First Live-Cell Based Product in The Iranian Drug List; ReColorCell®.Cell journal · 2023Article
- Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo.Frontiers in cell and developmental biology · 2023Review
- The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.Oxidative medicine and cellular longevity · 2022Review
- Vitiligo: What's old, what's new.Dermatology reports · 2021Article
- Strategies to Develop a Suitable Formulation for Inflammatory Skin Disease Treatment.International journal of molecular sciences · 2021Review
- Involvement of adenylate cyclase/cAMP/CREB and SOX9/MITF in melanogenesis to prevent vitiligo.Molecular and cellular biochemistry · 2021Review
- Dedifferentiation of human epidermal melanocytes in vitro by long-term trypsinization.Cell and tissue banking · 2021Article
- Plant-Derived Compounds as Promising Therapeutics for Vitiligo.Frontiers in pharmacology · 2021Review
- 42 °C heat stress pretreatment protects human melanocytes against 308-nm laser-induced DNA damage in vitro.Lasers in medical science · 2020Article
- Article
- Differentiation of adipose-derived stem cells to functional CD105Stem cell research & therapy · 2019Article
- Skin Pigmentation: Is the Control of Melanogenesis a Target within Reach?International journal of molecular sciences · 2018Article
- Skin Sarcoidosis on Both Vitiligo and Tattoos in the Same Patient: Report of an Exceptional Case and Pathogenetic Hypotheses of Intriguing Associations.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is an asymptomatic but cosmetically disfiguring disorder that results in the formation of depigmented patches on skin and/or mucosae. Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as progressing or stable based on the activity of the disease. Further, the extent of involvement can be limited (localized disease) or extensive (generalized disease). The treatment of vitiligo therefore depends on the clinical classification/characteristics of the disease and usually comprises of 2 strategies. The first involves arresting the progression of active disease (to provide stability) in order to limit the area involved by depigmentation. The second strategy aims at repigmentation of the depigmented area. It is also important to maintain the disease in a stable phase and to prevent relapse. Accordingly, a holistic treatment approach for vitiligo should be individualistic and should take care of all these considerations. In this review, we shall discuss the vitiligo treatments and their important clinical and molecular aspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.